ホーム › トリプルネガティブ乳がん › マサチューセッツ州
マサチューセッツ州におけるトリプルネガティブ乳がんの臨床試験
マサチューセッツ州内の拠点で、トリプルネガティブ乳がんに関する26件の研究が参加者を募集しています。
マサチューセッツ州内の都市
公式研究テキスト（英語）
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Massachusetts General Hospital, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06465069The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Dana Farber Cancer Institute, Boston
被験者募集中第1相
19歳以上 · 全性別 · 2026/10/01更新 · NCT06586957Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT05422794A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Massachusetts General Hospital Cancer Center ( Site 0091), Boston
- Dana Farber Cancer Institute ( Site 0090), Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06966700Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/21更新 · NCT05983432A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer
- Massachusetts General Hospital, Boston
被験者募集中
18歳以上 · 全性別 · 2026/09/15更新 · NCT07513311First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06657222Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
- 他4件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT05633654A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/28更新 · NCT07029399A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/18更新 · NCT07182149Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/17更新 · NCT07341867A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/08/10更新 · NCT06926868DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
- Dana-Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/06更新 · NCT06176261Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05579366Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Massachusetts General Hospital, Boston
被験者募集中第1相
18歳〜100歳 · 全性別 · 2026/07/29更新 · NCT06562192A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/28更新 · NCT06150664Sacituzumab Govitecan In TNBC
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
- Massachusetts General Hospital - North Shore Cancer Center, Danvers
- 他1件
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/17更新 · NCT04230109Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/13更新 · NCT07137416A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/29更新 · NCT05377996A Study of LY4175408 in Participants With Advanced Cancer
- Massachusetts General Hospital, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/23更新 · NCT07046923Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
- Dana-Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/04更新 · NCT04434040Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- Dana Farber Cancer Institute, Boston
- DFCI @ Foxborough, Foxborough
- DFCI @ Milford Regional Hospital, Milford
- 他1件
被験者募集中第2相
18歳以上 · 全性別 · 2026/04/29更新 · NCT04468061This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/04/02更新 · NCT06451497A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
- Massachusetts General Hospital, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/17更新 · NCT06908928Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- Massachusetts General Hospital, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2024/11/15更新 · NCT04787042ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。